Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT

v3.20.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Series A Preferred Stock
Series B Preferred Stock
Series C Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Total
Balances at beginning (in shares) at Mar. 31, 2018 500,000 1,160,240 2,318,012 23,068,280        
Balances at beginning at Mar. 31, 2018 $ 500 $ 1,200 $ 2,300 $ 23,100 $ 167,401,400 $ (3,968,100) $ (156,543,800) $ 6,916,600
Proceeds from sale of common stock for cash in February 2019 Public Offering, net of underwriting discount and expenses (in shares)       11,500,000        
Proceeds from sale of common stock for cash in February 2019 Public Offering, net of underwriting discount and expenses       $ 11,500 10,376,900     10,388,400
Stock-based compensation expense         3,443,400     3,443,400
Accrued dividends on Series B Preferred stock         (1,139,900)     (1,139,900)
Proceeds from sale of common stock and warrants for cash in private placement offerings (in shares)       5,025,939        
Proceeds from sale of common stock and warrants for cash in private placement offerings       $ 5,000 6,626,400     6,631,400
Proceeds from exercise of warrants (in shares)       403,800        
Proceeds from exercise of warrants       $ 400 605,300     $ 605,700
Proceeds from exercise of stock options (in shares)       29,250       29,250
Proceeds from exercise of stock options         43,900     $ 43,900
Fair value of common stock issued for PH94B license and PH10 option and license (in shares)       2,556,361        
Fair value of common stock issued for PH94B license and PH10 option and license       $ 2,600 4,247,400     4,250,000
Fair value of common stock and warrants issued for services (in shares)       175,000        
Fair value of common stock and warrants issued for services       $ 200 499,300     499,500
Increase in fair value attributable to warrant modifications         25,800     25,800
Net loss (24,589,600) (24,589,600)
Balances at end (in shares) at Mar. 31, 2019 500,000 1,160,240 2,318,012 42,758,630        
Balances at end at Mar. 31, 2019 $ 500 $ 1,200 $ 2,300 $ 42,800 192,129,900 (3,968,100) (181,133,400) 7,075,200
Stock-based compensation expense         3,820,800     3,820,800
Accrued dividends on Series B Preferred stock         (1,263,600)     (1,263,600)
Proceeds from sale of common stock and warrants for cash in private placement offerings (in shares)       650,000        
Proceeds from sale of common stock and warrants for cash in private placement offerings       $ 600 649,400     650,000
Proceeds from sale of warrants in private placement         300,000     300,000
Proceeds from sale of units of common stock and warrants for cash in public offering and concurrent private placement, shares       3,870,077        
Proceeds from sale of units of common stock and warrants for cash in public offering and concurrent private placement, amount       $ 3,900 2,695,100     2,699,000
Issuance of commitment shares and net proceeds of initial sale of common stock under equity line, shares       1,250,000        
Issuance of commitment shares and net proceeds of initial sale of common stock under equity line, amount       $ 1,200 525,100     526,300
Proceeds from exercise of warrants (in shares)       820,000        
Proceeds from exercise of warrants       $ 800 409,200     $ 410,000
Proceeds from exercise of stock options (in shares)               0
Increase in fair value attributable to warrant modifications         826,900     $ 826,900
Net loss               (20,774,000)
Balances at end (in shares) at Mar. 31, 2020 500,000 1,160,240 2,318,012 49,348,707        
Balances at end at Mar. 31, 2020 $ 500 $ 1,200 $ 2,300 $ 49,300 $ 200,092,800 $ (3,968,100) $ (201,907,400) $ (5,729,400)